Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Operating Leases (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Operating Leases for 5 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases fell 15.13% to $3.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.3 million, a 15.13% decrease, with the full-year FY2025 number at $3.3 million, down 15.13% from a year prior.
  • Operating Leases was $3.3 million for Q4 2025 at Rhythm Pharmaceuticals, down from $3.5 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $4.0 million in Q3 2024 to a low of $284000.0 in Q1 2024.
  • A 5-year average of $2.2 million and a median of $1.8 million in 2021 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: plummeted 73.61% in 2024, then soared 1251.76% in 2025.
  • Rhythm Pharmaceuticals' Operating Leases stood at $1.9 million in 2021, then tumbled by 35.22% to $1.3 million in 2022, then plummeted by 61.11% to $490000.0 in 2023, then skyrocketed by 703.67% to $3.9 million in 2024, then dropped by 15.13% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Operating Leases are $3.3 million (Q4 2025), $3.5 million (Q3 2025), and $3.7 million (Q2 2025).